Cardiomyopathy, Hypertrophic
A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).
Subtype terms (2)
More specific conditions that are subtypes of Cardiomyopathy, Hypertrophic in the MeSH hierarchy.
- Apical Hypertrophic Cardiomyopathy
- Cardiomyopathy, Hypertrophic, Familial
2 drugs (1 approved, 1 experimental)
Drugs by status
Approved for this indication (2)
Phase 4 trials (9)
Phase 3 trials (9)
Phase 2 trials (10)
Phase 1 trials (6)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (5)
Organization Involved with Phase 3 Indications (12)
- MyoKardia, Inc.
- National Heart, Lung, and Blood Institute (NHLBI)
- Harvard University
- Newcastle University
- University of Florence
- University of Ottawa
- University of Regensburg
- University of Calgary
- Heart Metabolics
- Heart and Stroke Foundation of Canada
- Assistance Publique - Hôpitaux de Paris
- Institute for Cardiovascular Diseases of Vojvodina
Organization Involved with Phase 2 Indications (16)
- AstraZeneca
- Novartis
- Array BioPharma
- Menarini Group
- Cytokinetics
- The Foundation Institute San Raffaele G. Giglio of Cefalù
- Aarhus University
- University of London
- Flinders University
- New England Research Institutes
- University of Birmingham
- University of Bordeaux
- University of Copenhagen
- British Heart Foundation
- University of Oxford
- Vita-Salute University of Milano. Italy
Organization Involved with Phase 1 Indications (5)